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HER2/neu is a transmembrane glycoprotein that is overexpressed in many tumors,
including ovarian and breast cancers. The HER2/neu peptide IISAVVGIL (GP2) is
recognized by tumor-specific cytotoxic T lymphocytes in the context of human class I major
histocompatibility complex (MHC) HLA-A2.1. One limiting-factor for using GP2 as a tumor
vaccine is its poor affinity for HLA-A2.1, even though it has the correct peptide-binding
motif. The research aims are to develop an accurate docking method for the binding of GP2
to HLA-A2.1, to understand the molecular forces that give rise to strong binding, and to
predict mutations that lead to new tumor vaccines. AutoDock and GOLD have been used for
docking calculations. The binding free energies from AutoDock correlate qualitatively with
experiment. The docked structures for 14 ligands from Autodock3 are in good agreement
with experiment. However, the ligands are not fully flexible. GOLD allowed full flexibility
to reproduce experimental GP2 structure.
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Chapter 1

Introduction

The study of the molecular interactions between the components of the immune
system and specific molecules of interest is essential for our understanding of disease
control as well as normal immune regulation. As is well known, immune system control
involves a complex interaction between T cells, T cell receptors (TCR’s), antigens and
antibodies. One essential component of immune control is the histocompatibility complex
molecule (MHC). These molecules are glycoproteins expressed at the surface of all
vertebrate cells. Their name arises from the fact that they are largely responsible for the
determining the compatibility of tissues between genetically different individuals [1].
T cell receptors act as ‘recognition sites’ for specific antigens, i.e. MHCassociated peptides. During their differentiation, T-cells become tolerant to complexes of
self-peptides and other self-molecules. Thus, if any novel molecule, i.e., from an
infectious agent, is introduced, they are most usually recognized as ‘foreign’ by T-cells
[2-4].
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1.1

Structures of class I MHC Proteins

Two classes of MHC proteins are distinguished: class I, and class II. Class I
molecules consist of three parts: a transmembrane protein, called the heavy chain, most
of which is exposed at the cell surface. Two segments of alpha helix form a groove
between them with two edges in the outermost domains. A small molecule (e.g., a short
peptide) attached noncovalently in the groove between the two alpha helices. The third
component of class I MHC proteins is a molecule of ß2-microglobulin (β2m), which is
also attached noncovalently. An example of crystallographic structure of class I MHC
molecules is shown in Figure1.1 [5].
An important characteristic of MHC proteins is their polymorphicity. The heavy
chain in the MHC molecule is extremely polymorphic in nature [3,6]. Indeed, a
characteristic of this family is the presence of hundreds of MHC alleles in a species.
When the influence of recombination is also taken into consideration with the high
degree of polymorphism, there is a heightened possibility of the expression of numerous
combinations of MHC alleles, and also a high degree of heterozygosity. Under such
genetic influences, it would be rare to find two unrelated individuals with an identical
combination of HLA genes [3]. HLA-A, HLA-B, and HLA-C are the ‘classical’ class I
molecules of humans. HLA stands for human leukocyte antigen primarily due to the fact
that the molecules were first studied on leukocytes [1]. These differ only in their heavy
chain, with all sharing the same type of β2m. All HLA molecules are encoded on
chromosome 6, with the exception of β2m, which is located on chromosome 15 [2]. A
human MHC molecule allele HLA-A2.1, one of the most common class I alleles [7,8], is
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dealt with in this thesis. In many cancers, HLA-A2.1 plays a significant role in antigen
presentation of both viral and tumor antigens [7,8]. The X-ray crystallographic structures
of HLA-A2.1 proteins complexed with a limited number of peptides have been resolved
[5, 9-15]. Figure 1 shows the X-ray structure of HLA-A2.1 protein complexed with a
molecule of β2m and a short peptide, IISAVVGIL (GP2) [5].

Figure 1.1: The X-ray structure of the MHC complex 1QR1, including the HLA-A2.1
protein, GP2 peptide, and a molecule of β2m. Backbones of the HLA-A2.1 and β2m
proteins shown in red and yellow colors. The peptide GP2 is shown in green color as a
ball-and-stick.
Stretches of beta conformation are represented by the broad yellow arrows
(pointing N → C terminal). Regions of α helix are shown as red helical ribbons. The
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pairs of violet spheres represent the disulfide bridges. The molecule of β2m is bound to
the junction of the α1 and α2 domains (at the blue line) and to the α3 domain (blue circle)
by noncovalent interactions only. A small peptide, shown in green color, is attached
noncovalently in the groove between the α helices of the α1 and α2 domains.
HLA-A2.1 and β2m expressed in Escherichia coli are produced as inclusion
bodies, purified and folded [5]. Crystals were grown by hanging drop vapor pressure [5].
The structure is a high-resolution X-ray structure that the resolution is 2.4 Å [5]. It is
believed that glycosolation sites are far from the binding groove that the binding is not
affected from it.

1.2

MHC-Associated Peptides

MHC proteins have a broad specificity providing different peptides to T cells,
whose activity is limited to these peptides presented by the MHC proteins [6]. There are
several hundred different MHC proteins within the human species, each having different
specificity [2]. Thus, MHC proteins bind many peptides with diverse sequences.
Class I molecules, both heavy and light chains, are synthesized in the endoplasmic
reticulum (ER) [3]. Cytosolic proteins are the source of peptides that are loaded on the
class I molecules. There is a common opinion about endopeptidase activity of the
proteasome that it partially degrades these cytosolic proteins.

The proteasome has

several activities and it is found in the cytosol [3]. The TAP molecule (transporter
associated with processing) carries these peptides into the ER [3]. The fate of these
peptides inside the ER lumen is not exactly known. According to one hypothesis class I
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MHC proteins is immediately loaded with these peptides after release from the
transporter [2]. Another suggest that peptides first binds to a chaperone, gpgp96, and
then are carried to class I MHC proteins perhaps with some trimming of the peptides
underway [3]. Regardless of these pathways, these peptides reach the class I MHC
molecule and binds into the groove shown in Figure 1.2, perhaps after a final trimming
step while already in touch with MHC [3].

Figure 1.2: Binding cleft of HLA-A2.1 complexed with GP2 peptide. GP2 binds in the
groove of HLA-A2.1 in an extended conformation.

Class I MHC proteins require three important factors for binding of peptides to
them. First, MHC-associated peptides have allele-specific lengths. HLA-A2.1 protein
requires 9±1 residue peptides [2-4]. Second, MHC-associated peptides have anchor
residues [2,16-19]. A subset of peptide amino acids in N and C termini, termed as anchor
residues are important as their side-chains are critical for interacting with polymorphic
complementary pockets in MHC peptide binding grooves [2,16-21]. The combination of
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amino acids that may bind at the anchor positions is known as the “peptide-binding
motif” [2, 5, 6, 19]. Third factor is called occupancy, i.e. binding within “specificity
pockets” that are primarily formed by the polymorphic residues within the binding cleft
of the MHC molecule [2, 20, 21]. Kuhns et. al. [4] stated that peptides that bind with high
affinity to a given allotype are typically found to have one of a few preferred amino acids
at each anchor position. The corresponding hypothesis is, peptides that do not have those
preferred amino acids at the anchor positions will not bind well [5]. Previous studies
explaining the role of anchor residues in binding of peptides to MHC proteins are in
agreement with the fact that anchor residues are required by MHC proteins [2,5,16-19].
However, a number of studies show that anchor residues are not sufficient for strong
binding, and there are factors other than peptide size and the presence of anchor residues
playing a decisive role in determining binding to HLA-A2.1 [17, 22-25]. The center
residues of MHC-associated peptides are shown to be important for the recognition by
TCRs as anchor residues in N and C termini are important for binding to class I MHC
proteins [17-26]. However, Buus et. al. [27] stated that other residues within the peptide
besides the anchors may also be used to generate increased binding affinity. Meng et. al.
[29] also support this concept and they reported that nonanchor residues are more tolerant
to mutations than the anchor residues.
As it can be seen from Figure 1.2, MHC-associated peptides have extended
conformation in the binding cleft. Also, all class I MHC associated peptides identified so
far have similar extended backbone conformations. Interestingly, the anchor positions, N
and C termini of the peptide, show further similarity in backbone conformation as shown
in Figure 1.3.
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Figure 1.3: Overlay of 14 different MHC-associated peptide X-ray structures. PDB
codes are 1QR1 [5], 1HHI [9], 1HHJ [9], 1HHK [9], 1HHH [9], 1JF1 [10], 1JHT [10],
2CLR [11], 1I4F [12], 1DUY [13], 1DUZ [13], 1B0G [14] and 1QSE [15]. Backbones of
the aminoacids in positions 1, 2, 8, and 9 do not vary with the sequence.
To summarize, peptides that bind to class I MHC pproteins are usually restricted
in length and often contain anchor residues at specific locations on the peptide. The
anchor residues are required for binding to class I MHC proteins but may not be
sufficient to generate a strong binding. The center residues play an important role in
allele-specific recognition of antigenic peptides.
The identification and characterization of principles that govern peptide binding
to specific structures on MHC proteins is of critical importance in the context of vaccine
development and therapeutics, and ultimately to also enhance our knowledge of the basic
principles of protein-protein recognition.

8

1.3

T cell / MHC Interaction
The surface of each T cell displays thousands of identical T cell receptors (TCRs).

The TCR binds a bimolecular complex of a small peptide, i.e. a fragment of an antigen,
and MHC molecule displayed at the surface of the antigen-presenting cell (APC). Most of
the T cells in the body belong to one of two subsets. There are two types of T cells in the
body. They differ from the glycoproteins that they have on their surfaces: CD4 and CD8.
Which of these molecules is present determines what types of cells the T cell can bind.
CD8+ T cells bind epitopes that are part of class I MHC proteins. Class I MHC proteins
are expressed by almost all the cells of the body [1].
CD8+ T cells are specific to antigens presented by class I molecules. Most CD8+ T
cells are cytotoxic T cells (CTLs). They might destroy cells whose class I epitope they
recognize. Viral or tumor-associated cells might be destroyed after the recognition by the
T cells specific to that antigen [2-4, 27-31]. To summarize, T cells function as protection
mechanism in the body agains viruses or tumors. The pathway of the class I MHC
proteins are shown in Figure 1.4.

9

Figure 1.4: The pathway of class I MHC proteins [1]. The proteins synthesized within
the cell are chopped up into small peptides. Then, these peptides bind to MHC proteins.
The peptide-bound MHC proteins are transported to the cell surface, where T cell
receptors will bind to them.

1.4

Vaccination Strategies against Cancer
Current strategies of tumor vaccination involve utilizing whole tumor cells, or

targeting defined antigens [32]. The latter, i.e. antigen-specific vaccination strategies can
be divided into two subgroups; antigens not normally expressed somatic cells, and
antigens that are normally expressed on somatic cells [32]. The latter class of tumor
antigens includes tissue-specific antigens, such as the melanoma/melanocyte antigens,
and antigens that are widely expressed in normal tissue albeit at very low levels (e.g. p53
and Her-2/neu) [32]. To exploit these antigens as targets for immunotheraphy one has to
take into account two major factors: the existence of immunological tolerance, and the
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possibility of inducing autoimmune reactions to normal tissues [32]. Work done in
animal models and results from a number of clinical studies indicated that efficient
immunity against autoantigens can be obtained as long as expression of the antigen
concerned is not excessively high and widespread [32].
The HER-2/neu oncogenic protein is a well defined tumor antigen [33]. It is
shared among multiple tumor types, including breast and ovarian cancers [33]. Patients
with HER-2/neu protein over-expressing breast, ovarian, non-small cell lung, and
prostate cancers have been shown to have a pre-existent T cell immunity to HER-2/neu
[33-35]. In general, endogenous immunity to HER-2/neu detected in cancer patients
demonstrates two prominent characteristics [33]. First, HER-2/neu specific immune
responses are found in only a minority of patients whose tumors over-express HER2/neu. Secondly, immunity, if detectable, is of low magnitude. These observations have
led to the development of vaccine strategies design to boost HER-2/neu-specific T cell
response in patients [33-35]. HER-2/neu is a non-mutated self-protein, therefore vaccines
must be developed based on immunological principles focused on circumventing
tolerance [33-35]. Early results in clinical trials demonstrate that significant levels of
HER2/neu can be generated with active immunization [33]. Importantly, it was learned
that the antigen-specific T cell immunity remains detectable after the completion of
vaccinations [33].
In conclusion, with the recent progress in the study of natural and experimentally
induced immunity, it is appears that immunotherapy, particularly in relation to cancer
treatment, is entering a new era. The continuation of such progress may depend on the
progressive development, refinement and use of antigen-specific cancer vaccines in
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patients displaying less-progressed stages of disease.

More powerful and accurate

methodologies may also arise with closer assimilation between, for instance
immunologists/oncologists specializing in cell-specific aspects of vaccine development
and those researchers in other less ‘classical’ fields of chemistry. For instance, it is hoped
that the computational modeling of protein binding may help to catalyze biological
research by assessing the specificity, force and predictability of certain protein binding
characteristics. In the present thesis, it is this latter field that will be used examined in the
context of immunotherapeutics, in an attempt to assess, and hopefully enhance, the
predictability of vaccine design.
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Chapter 2

Goals of MS Research

2.1

Statement of Problem
As previously stated, the immune system has the capability of recognizing the

tumor-associated peptides in the context of class I MHC proteins and ultimately
destroying the tumor-associated cell. However, not all tumors are recognized efficiently.
One reason hypothesized for poor T cell recognition of tumor-associated peptides is poor
binding of potentially immunologically reactive peptides to class I MHC proteins [5]. If
the peptides dissociate from class I MHC proteins too quickly, the cell presenting the
peptides do not have a sufficient concentration of the specific peptide bound MHC at the
surface of the cell to be recognized by circulating T cells [5].
It is known that peptide vaccines have the potential to induce immune responses
in vivo that are specific for epitopes on the tumor cells and therefore could have
therapeutic potential [33-36]. Several tumor-associated peptides have been identified in
breast and ovarian cancer patients [32-36]. The proto-oncogene product HER-2/neu is
overexpressed in approximately 30% of patients with breast and ovarian cancer, and such
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tumors are associated with a worse prognosis than HER-2/neu negative tumors [32-36].
Many peptides derived from the HER-2/neu have been shown to be recognized by
cytotoxic T cells derived from HLA-A2 patients with breast cancer and other carcinomas
[26,32-36]. In particular, IISAVVGIL (GP2) peptide (HER-2/neu 654-662) is recognized
by T cell lines developed from patients [5,26]. Thus, it is one of the potential candidates
for tumor vaccines. [5,26]. GP2 binds very poorly even though it is predicted to bind well
based upon the presence of the correct HLA-A2.1 peptide binding motif [4,27]. GP2
(IISAVVGIL) has the anchor residues ILE at position 2 and LEU at position 9 [5,28].
The crystallographic structure of the GP2 bound to HLA-A2.1 [5] provided an
explanation for the poor binding: The central region of the peptide (positions 5, 6, and 7)
is flexible, i.e. has multiple conformations, and does not make stabilizing contacts with
residues in the MHC binding cleft. It is reported that the electron density map of GP2,
which is shown in Figure 2.1, shows uninterpretable electron density within the center of
the peptide (the residues VVG at positions 5, 6, and 7, respectively) [5]. Substitutions at
the 2 and 9 anchor positions resulted in little or no improvement in binding affinity, but
altered the conformation of the putative T cell receptor contact region in the center [37].
Therefore, the next logical step is to explore substitutions at positions other than the
primary anchors by focusing on the flexible P5-P7 region. Some of the previous studies
addressing the recognition problem of HLA-A2.1-restricted peptides are reviewed briefly
in the next subsection of this thesis.
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Figure 2.1: Electron density map of GP2 peptide [6]. There is an interpretable electron
density in the region of positions 5, 6, and 7 [6].

2.2

Previous Studies
Since the binding of peptides to MHC protein is a prerequisite for the recognition

by TCR, a significant number of effort has gone to investigate the binding of small
peptides to MHC proteins and to improve the binding by performing mutations on the
peptides as a strategy [see ref.28 as a review] [5,24-26,37-57]. To investigate the poor
binding, several GP2 mutations have been made experimentally as high affinity ligands
for cancer immunotherapy [5,26]. Kuhns et. al. [5] measured the relative binding
constants of GP2 and several GP2 analogs as well as a high affinity ligand, called MelA,
and its analogs to MHC. The GP2 and MelA analogs were obtained by modifying the
anchor residues since it is thought that center residues were important for T cell response.
The results showed that although anchor substitutions of MelA improved binding
significantly to MHC, anchor substitutions did not significantly increase the binding
affinity of GP2 to MHC. This is because these anchor substitutions did not address the
fundamental problem that the peptide has in the center. That is the center residues do not
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make stabilizing contacts with the binding cleft of the class I MHC molecule. In their
subsequent article [37], it is shown that the anchor residue mutations alters the
conformation of the T cell receptor contacts, i.e., the center of the peptide. Tanaka et. al.
[26] performed modifications on anchor residues together with the position1 and studied
the binding affinities as well as the CTL response. A high affinity peptide FLU [PDP
code 1HH1, 9] was used as a positive control. Only the residues at positions 1, 2, and 9
were modified since center residues were thought to be important for T cell responses.
However, as it is stated by Sharma et. al. [37] that, altering one residue at positions 2 and
9 changes the peptide structure in the center. In addition, Meng and Butterfield [28]
reported that non-anchor residues can also be used for mutations besides the anchor
residues. By introducing the third modification at position 1, Tanaka et. al. were able to
improve both the binding affinity to HLA-A2 and the recognition by GP2-specific CTL.
There are a number of theoretical studies to investigate the peptide/HLA-A2.1
binding properties, though none of them examines GP2 specifically [24,25,38-57]. Meng
et. al. [48] studied influenza matrix protein peptide FLU by using molecular dynamics
simulations. They concluded that a dynamic, groove based water network contributes to
the formation of the FLU/HLA-A2 complex. A flexible network of water molecules in
the binding groove might allow the protein side chains to adjust their conformation in
response to different peptides. Also, they proposed that the presence of groove-based
water might play a role in determining the affinity of specific peptide-MHC interactions.
Froloff et. al. [42] described a methodology to calculate the binding free energy of a
protein-ligand complex using a continuum model of the solvent. A formal

16
thermodynamic cycle is used to decompose the binding free energy into electrostatic and
non-electrostatic contributions. In this cycle, the reactants are discharged in water,
associated as purely nonpolar entities, and the final complex is then recharged. The total
electrostatic free energies of the protein-ligand complex in water are calculated with the
finite difference Poisson-Boltzman method. The nonpolar (hydrophobic) binding energy
is calculated using a free energy-surface area relationship, with a single alkane/water
surface tension coefficient. The loss in backbone and side-chain configurational entropy
upon binding is estimated and added to the electrostatic and the nonpolar components of
the binding free energy.

Rognan et. al. [45] developed a free energy scoring function,

Fresno, to predict the binding free energy of peptides to class I MHC proteins. Fresno has
the form:

∆Gbinding = K + α(HB) + β(LIPO) + γ (ROT) + δ(BP) +
ε(DESOLV)

(1)

where, HB stands for H-bond, LIPO for lipophilic, ROT for rotational, BP for buriedpolar terms, and last term for desolvation scores. First, ChemScore scoring function is
used to calculate the binding energies of the training set, i.e. peptide/HLA-A2.1
complexes of PDB codes 1HHG, 1HHH, 1HHI, 1HHJ, and 1HHK. Then, the Fresno is
obtained by recalibrating the computed values fitting to the experimental data. It differs
from the other scoring functions [58-62] developed before mainly by the expilicit
treatment of ligand desolvation and of unfavorable protein-ligand contacts. This method
requires the three-dimensional structures of protein-ligand complexes. Predictions were
more accurate for HLA-A2 binding peptides as the training set had been built from

17
experimentally determined structures (average error: 3.1 kJ/mol). For the homology
model-derived equation, i.e. the computed data is fitted to the homology modeled data
since the experimental data were not available, the average error in predicting binding
free energy of peptides to the MHC molecule of mouse (Kk) was higher (5.4 kJ/mol) but
still acceptable. Then, in their next paper [53], the Fresno has been compared to six
universal scoring functions (ChemScore, Dock, FlexX, GoldScore, Pmf, Score). Fresno
performed better than other six scoring functions. Another computational study of
Rognan et. al. [50] investigated the mouse histocompatibility molecule (Kk) complexed
with an Influenza Hemagglutinin peptide, Ha255-262, and the TCR by using the tools of
homology modeling as well as molecular dynamics. First, Kk was built by homology
modeling and subsequently refined by simulated annealing and restrained molecular
dynamics. TCR models are then docked into the Ha255-262/Kk model. The experimental
mutations have been examined systematically and the computational results are in good
agreement with the experiment. It is believed that such models may guide the future
rational experimentation. In another significant molecular modeling study, Michielin et.
al. [49] presented a methodology for generating a homology model of a TCR-MHCpeptide complex. It is shown that by using computational tools together with the
experimental mutation data, the interactions of complex biological systems can be better
understood. This model investigates the effects of mutations on the binding of TCR to its
ligand and moreover suggests new mutations for TCR. The mutational data obtained is
qualitative and it is noted that for quantitative analyses, more computer-intensive
methods need to be used.

2.3

Goals of this research
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The long-term goal of this computational study is to develop a protocol so that
better binding GP2 analogs for cancer immunotherapy can be designed. To do this the
following short-term goals have been established. First of all, it is planned to develop a
practical and accurate docking method to investigate the binding of GP2 to HLA-A2.1.
Then, gain insight into the molecular forces that give rise to strong binding by performing
the same type of calculations on different peptide/MHC complexes including strong,
moderate, and weak binders. Finally, propose mutations that could lead to new tumor
vaccines.
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Chapter 3

Computational Strategy

The docking calculations for peptide/HLA-A2.1 complexes have been planned as
a strategy to obtain the best ligand confirmation inside the binding groove. Two main
steps have been followed. First, the experimental data needed to be reproduced by
performing docking calculations on ligand/HLA-A2.1 complexes. Second, the GP2
analogs, i.e. the mutated GP2 ligands have been docked by using the same docking
method to obtain a better binding ligand. AutoDock version 3.0.5 [55] was used for both
purposes. Then the GP2 peptide have been investigated further by using GOLD program
[55]. The genetic algorithm has been used as implemented in AutoDock and GOLD
programs. In the following parts of this thesis, simple introductory information on
docking studies and genetic algorithms is provided.

3.1

Docking studies
Molecular docking predicts the orientation of the ligands bound to receptors by

assuming that the receptor conformation is known [66]. Molecular docking is a fast
method to explore substrate/receptor complexes in the field of drug discovery as well as
in understanding biochemical processes [66]. The major techniques used for molecular
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docking are: genetic algorithms, simulated annealing, molecular dynamics, Monte Carlo
methods, distance geometry methods, point complementary methods, fragment-based
methods, tabu searches, and systematic searches [66].
Docking procedures are composed of two components: a search algorithm and a
scoring function. The search algorithm finds different conformations for the ligand by
using one of the methods listed above. Systematic searches explore all possible binding
modes between the ligand and receptor. However, this takes a huge amount of
computational time especially for large flexible ligands. The amount of conformational
space explored and the computational time required for the search must be balanced.
Scoring functions are used to rank the different conformations obtained by the search
algorithm. A good scoring function distinguishes the experimentally obtained
conformation from all other conformations explored through the search algorithm. The
major scoring methods are empirical free energy scoring functions, molecular mechanics
force fields, and knowledge-based functions [66].
Some of the docking programs currently in use are the DOCK [67,68], GOLD
[64], AutoDock [63], Surflex [69], MOE-Dock [70,71], FlexX [72-75], FTDOCK [7679]. The differences between them are derived from the different search algorithms or
different implementation of the same algorithms, and different scoring functions. Most of
these programs hold the receptor rigid and allow a certain degree of flexibility to the
ligands. The docking methodology in AutoDock and GOLD is explained in the
methodology section in detail.

3.2

Genetic algorithms
The Genetic algorithms [80] are considered to be stochastic global optimization
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methods. Since they do not use gradient information, they can be applied various
different types of optimization problems. The genetic algorithm searches the parameters
forming the conformational space simultaneously. Judson [80] simply explains the
genetic algorithms by using Figure 6 as an example. Three local minima labeled as I, II
(the global minimum), and III are shown in the f(x) function. Then, the genetic algorithm
terms are introduced; fitness, populations, and chromosomes. The function f(x) is the
fitness. The populations are set of individuals sampling the conformational space.

f(x)

III
I

II

x

Figure 3.1: A sample one-dimensional fitness function illustrating local minima
labeled as I, II, III, and the global minimum labeled as II [80].
The x in the example denotes for one of the chromosomes, which are the
parameters forming each individual. Other genetic algorithm terms are mutations,
selection, crossovers, and migrations [81]. The mutation operator obtains the individuals
by randomly changing the chromosomes. The best individuals based on the fitness
function are then selected for crossover. The crossover allows an exchange of a set of
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chromosomes from one parent to another. The migration moves individual chromosomes
from one sub-population to another. The mutation, crossover, and migration procedures
continue until some stopping criteria are met. The following section includes the
information on how genetic algorithms were implemented in AutoDock and GOLD
programs.
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Chapter 4

Methodology

This section examines AutoDock and GOLD methodologies, including
information on how those programs work and the details of docking studies performed in
this study.
The crystal structures of 14 peptide/HLA-A2.1 complexes were obtained from the
Protein Data Bank (PDB) [82] having the PDB codes of 1QR1 [5], 1HHI [9], 1HHJ [9],
1HHG [9], 1HHK [9], 1HHH [9], 1JF1 [10], 1JHT [10], 2CLR [11], 1I4F [12], 1DUY
[13], 1DUZ [13], 1B0G [14], and 1QSE [15]. Docking studies were performed on these
systems by utilizing AutoDock program [63]. The 1QR1 complex, i.e. the GP2/HLAA2.1 system has been investigated in GOLD program [64] since in AutoDock, the
backbone of the GP2 ligand had to be fixed. GOLD allows full flexibility for the ligands.
The energy relaxations in MOE program [71] were performed before all docking
calculations to obtain the structures that are free of steric clashes. The details of these
energy minimizations are given in section 5.2.

4.1

AutoDock Version 3.0.5
The program AutoDock was developed to provide an automated procedure for

predicting the interaction of ligands with biomacromolecular targets. The docking
simulation is carried out using one of a number of possible search methods. The
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Lamarckian genetic algorithm and the Monte Carlo simulated annealing are available in
AutoDock. The receptor is considered as rigid, and the allowed flexibility for the ligand
is 32 torsion angles. The docking methodology in AutoDock is examined in the following
four sub-sections: Preparation of the ligand and receptor, the Autotors and Autogrid
procedure, the genetic algorithm implementation, and the fitness function and evaluation
of the free energy.
4.1.1 Preparation of the Ligand and Receptor
First the docking box has been placed into the active side of the receptor. For
GP2, a docking box with a grid consisting of 92 X 70 X 70 points and 0.375 Å grid
spacing were employed. The box was oriented so that the long side was along the
direction of the center of binding site to the center of the entrance of the binding site. In
this orientation, the box included the entire binding site and some area just outside of the
binding pocket entrance. The docking boxes of sizes between 82 X 60 X 60 and 110 X 80
X 80 with 4 grid point increments have been used in the calculations. The size 92 X 70 X
70 has been found optimum so that the ligand is free to have different conformations in
the binding cleft and also it is small enough to save the computational time. The size and
location
in
4.1.

this

of
study

the

docking box used

is

shown in Figure
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Figure 4.1:

The size and location of docking box

The degree of flexibility to be assigned to the ligand can be imported by using the
Autotors utility. Autotors uses a “Rigid Root” as a starting point for the “torsion angle
tree” [reference 90 has detailed information on torsion tree algorithms].
4.1.2

The Autogrid Procedure
AutoDock requires pre-calculated grid maps, one for each atom type present in

the ligand being docked. This helps to make the docking calculations extremely fast.
These maps are calculated by AutoGrid. A grid map consists of a three dimensional
lattice of regularly spaced points, surrounding (either entirely or partly) and centered on
some region of interest of the macromolecule under study. Each point within the grid
map stores the potential energy of a ‘probe atom’ or functional group that is due to all the
atoms in the macromolecule. Figure 4.2 illustrates the main features of a grid map [63]:
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Figure 4.2:

Docking box and grid points [63]. In the figure, the whole protein is in the

docking box which is defined by the grid points with a user defined grid spacing.

The energetics of a particular substrate configuration is found by tri-linear
interpolation of affinity values of the eight grid points surrounding each of the atoms in
the substrates. The time to perform an energy calculation using the grids is proportional
only to the number of atoms in the substrate, and is independent of atoms in the protein.
4.1.3

The Genetic Algorithm Implementation
The particular arrangement of a ligand and a protein is defined by state variables,

which include a set of variables describing the translation, orientation, and conformation
of the ligand with respect to protein. Each state variable corresponds to a gene, and the
ligand’s state corresponds to a genotype, whereas its atomic coordinates correspond to
the phenotype. In AutoDock implementation [63], the chromosome is composed of real
valued genes: three Cartesian coordinates for the ligand translation; four variables
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defining a quaternion specifying the ligand orientation; and one real-value for each ligand
torsion angle, in that order. The genetic algorithm begins by creating a random
population of individuals, where the number of individuals in the population is user
defined. For each random individual in the population, random values are assigned for
the genes. A loop over generations then takes place, repeating until the maximum number
of generations or the maximum number of energy evaluations is reached, whichever
comes first. A generation consists of five stages: mapping and fitness evaluation,
selection, crossover, mutation, and elitist selection, in that order. Mapping translates from
each individual’s genotype to its corresponding phenotype. This allows each individual’s
fitness to be evaluated. The fitness function and the energy evaluation are explained in
the next sub-section. Every time an individual’s energy is calculated. This is followed by
proportional selection to decide which individuals will reproduce. Crossover and
mutation are performed on random members of the population according to user-defined
rates of crossover and mutation. First, crossover is performed. The new members are
replaced the parents in the population, keeping the population size constant. Crossover is
followed by mutation. Optional user-defined integer parameter elitism determines how
many of the top individuals also automatically survive into the next generation. The
genetic algorithm iterates over generations until one of the termination criteria is met.
4.1.4

The Fitness Function and Free Energy Calculation
The fitness is the sum of the intermolecular interaction energy between the ligand

and the protein, and the intramolecular energy of the ligand. At the end of each docking,
AutoDock reports the fitness (the docked energy), the state variables, the coordinates of
the docked conformation, and the estimated free energy of binding (∆G).
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∆G calculation including the solvation effect in AutoDock is shown in Equation 2
[63]:

 Aij Bij 
 Cij Dij 
∆G = ∆Gvdw ∑  12 − 6  + ∆Ghbond E (t )  12 − 10 
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rij 
rij 
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 ij
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(2)
The Lennard-Jones 12-6 dispersion-repulsion term is first, the second is a
directional 12-10 H-bonding term, where E(t) is a directional weight based on the angle,
t, between the probe and the target atom, the third term is a screened Coulombic
electrostatic potential, the fourth term is a measure of the unfavorable entropy of ligand
binding due to the restriction of conformational degrees of freedom, which is
proportional to the number of of sp3 bonds in the ligand, Ntor, and finally the last term
accounts for the desolvation effect. For desolvation, the pairwise, volume-based method
of Stouten et. al. is used [63]. This method has the advantage that it is consistent with the
pre-calculated affinity grid formulation used by AutoDock [63]. For each atom in the
ligand, fragmental volumes of surrounding protein are weighted by an exponential
function and then summed, evaluating the percentage of volume around the ligand atom
that is occupied by protein atoms [63]. This percentage is then weighted by the atomic
solvation parameter of the ligand atom to give the desolvation energy [63]. The full
method may be broken into four separate components: burial of apolar atoms in the
ligand, burial of apolar protein atoms, burial of polar and charged atoms in the ligand,
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and burial of polar and charged protein atoms [63]. Great success has also been reported
in using simply the amount of hydrophobic surface area buried upon complexation as a
measure of the ‘hydrophobic effect’, so they tested several formulations that included
only the volume lost around ligand carbon atoms [63]. The burial of polar atoms caused
particular problems. Apart from the volume-based method, a simpler formulation for the
solvent transfer of polar atoms has been tested, where a constant term corresponding to
the favorable free energy of interaction of a polar atom with solvent is estimated, and this
is substracted from the binding free energy [63].

4.2

GOLD Version 2.0
GOLD [64] (Genetic Optimization for Ligand Docking) is an automated docking

program that uses genetic algorithm to search the conformational space and allows full
flexibility for acyclic ligands and partial protein flexibility in the neighborhood of the
protein binding cleft [64]. The docking methodology of GOLD will be examined in three
parts: initialization of the protein and ligand, genetic algorithm implementation, and the
fitness function.
4.2.1

Initialization of the Protein and Ligand
GOLD needs a user defined docking sphere that is placed within the binding cleft

of the protein with a user defined center and a radius. The center can be a point, or an
atom. Since there are X-ray crystal structures for ligands bound to HLA-A2.1 receptors,
the binding site of the receptor is already known. The center of the binding cleft has been
placed by using CHARMM program [86]. The receptor atoms within the 10 Å distances
of ligand atoms were selected and the center of the selected volume obtained by using
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‘stats’ option. The coordinates of the center is then found (4.00, 16.1, -6.70) in x, y, z
directions, respectively. As a radius going along with this center; 20, 25, and 30 Å have
been used. The 20 Å radius was found optimum so that the computational time and the
accuracy can be balanced. Figure 4.3 shows the docking sphere used in the calculations.
The protein is considered as rigid except OH groups of SER, THR and TYR, and
NH4+ group of LYS in the active site neighborhood. The ligand can be prepared as fully
flexible. The simplest constraints to apply to the ligand are keeping the ring corners,
amide bonds, planar nitrogens, and/or internal hydrogen bonds constant. The other
constraints available are the covalent constraints, distance constraints, H-bond
constraints, structure-based constraints, and similarity constraints. The default value for
the number of runs, which varies between 1 and 50, is 10. The protein and ligand input
files must be in pdb or tripos mol2 format. The latter is suggested. If the pdb format is
used, the program will assign the partial charges using a modified Tripos force field.
Since mol2 files contain the partial charge information, different force fields can be used
to prepare the mol2 files. In this study, the input files were prepared by using MOE
program [83] and mol2 files are used.
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Figure 4.3: The size and location of docking sphere. The center coordinates are (4.00,
16.1, -6.70) in x, y, z directions, respectively with 20 Å radius has been used in docking
calculations in GOLD.
4.2.2

Genetic Algorithm Implementation
GOLD uses a steady-state operator-based genetic algorithm to sample the

conformational space and ligand binding modes [64]. This genetic algorithm is illustrated
in Figure 4.4 [64].
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1. A set of reproduction operators (crossover, mutation, etc) is chosen. Each operator is
assigned a weight.
2. An initial population is randomly created and the fitnesses of its members determined.
3. An operator is chosen using roulette wheel selection based on operator weights.
4. The parents required by the operator are chosen using roulette wheel selection based on
scaled fitness.
5. The operator is applied and child chromosomes produced. Their fitness is evaluated.
6. If not already present in the population, the children replace the least fit members of the
population.

7. If 100000 operators have been applied stop otherwise go to 3.
Figure 4.4:

Genetic algorithm implementation in GOLD [64].

There are three operators used: mutation, crossover, and migration. The mutation
operator creates the individuals in each population by randomly changing the rotatable
bonds in the protein and ligand. Torsion angle values vary between -180° and 180° in
step-sizes of 1.4°. The default values for the number of individuals in one population and
number of populations are 100 and 5, respectively. The crossover operator provides the
exchange of chromosomes between the individuals. The migration operator copies an
individual from one population to another population. Operators were chosen using
roulette-wheel selection based on operator weights. These weights were chosen so that
crossover and mutation were applied with equal probability and migration was applied
5% of the time. After reaching the default value of number of operators, 100000, the
algorithm terminates.
After a conformation of the ligand and protein binding cleft generated, the ligand
is placed within the active site using a least squares fitting procedure. Then, its fitness
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score, which is explained in the next sub-section, is evaluated.

4.2.3 The Fitness Function
Two different scoring functions are available in GOLD: ChemScore and
GoldScore [64]. Chemscore was derived empirically from a set of 82 protein-ligand
complexes for which measured binding affinities were available. The ChemScore
function was trained by regression against measured affinity data. The calculation of free
energy of binding (∆Gbinding) is shown in Equation 3.

∆Gbinding = ∆G0 + ∆Ghbond + ∆Gmetal + ∆Glipo + ∆Grot

(3)

Each component of this equation is the product of a term dependent on the magnitude of
a particular physical contribution to free energy and a scale factor determined by
regression. The final ChemScore value is then obtained by adding a clash penalty and
internal torsion terms, which prevents close contacts in docking and poor internal
conformations. Covalent and constraint scores may also be included.

ChemScore = ∆Gbinding + Pclash + cinternalPinternal + (ccovalentPcovalent +
Pconstraint)

(4)

The GoldScore fitness function is composed of four components: protein-ligand
hydrogen bond energy (external H-bond), protein-ligand van der Waals (vdw) energy
(external vdw), ligand internal vdw energy (internal vdw), and ligand torsional strain
energy (internal torsion). Optionally, a fifth component, ligand intramolecular hydrogen
bond energy (internal H-bond), may be added. Empirical parameters used in the fitness
function (hydrogen bond energies, atom radii and polarizabilities, torsion potentials,
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hydrogen bond directionalities, etc.) are taken from GOLD parameter file, which can be
edited by the user. The external vdw score is multiplied by a factor of 1.375 when total
fitness score is computed. This is an empirical correction to encourage protein-ligand
hydrophobic contact. The final GoldScore value is stated in the following expression.

GoldScore = - (H_Bond_Energy + Internal_Energy + Complex
Energy)

(5)

The first term denotes for hydrogen bonding energy, which is determined by taking the
combinations of all donor and acceptor atoms whether they form a hydrogen bond. The
internal energy of the ligand, which is the sum of the ligand steric and torsional energies,
is calculated by using molecular mechanics expressions. The steric energy was calculated
using a 6-12 potential of the form:

Eij =

C
D
−
dij12 dij6

(6)

The torsional energy Eijkl is calculated by using the Tripos forcefield of the form:

Eijkl

 nijkl

1
= Vijkl 1 +
cos( nijkl .ωijkl ) 
2
 nijkl


(7)

The last term is a pairwise energy obtained for the steric energy of interaction between
the protein and the ligand. A 4-8 potential of the following form with linear cut-off was
used to calculate the interaction energy between the ligand and the protein.
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Eij =

A B
− 4
8
dij dij

(8)

The cut-off distance used was 1.5 times the sum of the van der Waals radii of the atoms.
The 4-8 potential was parametrized to reproduce the minimum of the more usual 6-12
potential.
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Chapter 5

Results and Discussion

5.1 Why GP2?
There are two primary reasons to study GP2 bound MHC proteins in detail. The
first is to understand how class I MHC binds peptides. There is a great deal known about
how class I MHC binds many peptides. Unfortunately, there is very little information
known about how the protein binds any particular peptide. There are many examples of
crystal structures of high affinity peptides bound to class I MHC. If a self-peptide binds
to class I MHC with high affinity, there is a larger concentration of peptide bound MHC
at the cell surface, and thus a greater chance that T cells would be able to recognize the
complex well. However, GP2 bound complex has a low affinity, a poor thermal stability,
and a very short cell surface half-life. Thus, GP2 is a perfect example of a poor binding
peptide and as such offers the first opportunity to understand poor binding.
The second reason to examine GP2 is that poor affinity peptides are potentially
better targets for immunotherapy [5]. It is known that the patients in breast cancer have
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significant amount of GP2-specific T-cells. Peptides with poor affinities like GP2 have
been believed for cancer immunotherapy, because it is more likely that the immune
system has not become tolerant to them. GP2 is therefore a good candidate for study.

5.2

Docking results from AutoDock
Docking studies have been performed to address the binding affinity of GP2 to

HLA-A2 using the X-ray crystallographic structure of GP2/HLA-A2.1 complex [5].
Partial energy minimizations have been performed on all systems using the Amber 94
force field [83] and the MOE program [71] to avoid the steric clashes. The default
sequence of minimization methods in MOE program has been used for partial energy
minimizations.
For weaker binding peptides, such as GP2, where all degrees of freedom were
free except for those associated with the amide bonds, the reported X-ray structure could
not be reproduced (1QR1). With the backbone fixed, the docking studies returned a
similar structure to experiment. This led us to use a different docking program, GOLD,
for GP2/MHC complex. GOLD results for GP2 are discussed in section 5.3. However,
interestingly, for other ligand-MHC complexes (1HHI, 1JHT, and 1B0G), the
experimental data have been reproduced with much better RMSD only by keeping amide
bonds fixed. The results from the docking studies on 1QR1 and 1HHI are presented in
detail in Figures 4 and 5.
The ligand has been treated two different ways for docking calculations. First by
keeping the backbone conformation fixed, then by keeping only amide bonds fixed. The
receptor has been taken as rigid in all docking calculations. 65 crystallographic water
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molecules have been retained and implicit solvation effect has been added.
The systems used for docking studies in Autodock are GP2-MHC molecule:
1QR1, other ligand-MHC proteins: 1HHI, 1HHJ, 1HHG, 1JF1, 2CLR, 1HHK, 1HHH,
1I4F, 1JHT, 1DUY, 1DUZ, 1B0G, 1QSE and MHC proteins bound to GP2-analogs
(experimental proposed modifications). The docking studies were carried out in different
manners, as described below.
5.2.1

GP2/MHC Docking Study
Starting with the X-ray crystallographic structure [5], GP2/MHC complex has

been partially energy minimized and investigated by docking. The receptor and the
backbone conformation of GP2 have been kept fixed in docking calcualtions. The method
and details of docking are identical to those described above. The MOE program has
been used to calculate the root mean square deviation (RMSD) between the experimental
and docked structures. In this procedure, a set of 3D protein structures are superposed in
such a way as to maximize their spatial overlap. Such a superposition is useful because it
highlights both the regions of conserved structure and the areas of divergence or
modification in the protein set. A weighted non-linear optimization is used to determine
the solid-body transformations required to maximize the superposition of the protein
atomic coordinates. Then, the RMSD between protein atomic coordinates is taken to be:

M

N kl

k =1 l > k

i =1

∑∑ vkl ∑ wi Rk ( xik − tk ) − Rl ( xil − tl )

2
(9)

where, M is the number of proteins, Nkl is the number of corresponding atoms, vkl is the
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protein-to-protein importance weights, wi is the importance weight of each atom
correspondence, Rk and Rl are the rotation matrices, xik are the coordinates of the ith
corresponding atom in the kth protein, xil are the coordinates of the ith corresponding atom
in the lth protein, and tk and tl are the translation vectors [34].
All atoms has been taken into account for calculating the superposition except
hydrogen atoms. The comparison of experimental and docked structure of GP2 is shown
in Figure 5.1.

Figure 5.1:

Overlay of experimental and docked GP2.

The RMSD has been calculated as 1.42 Å, while the resolution of the X-ray is
2.40 Å [4]. The predicted GP2 structure is in good agreement with the experimental
findings since the RMSD value from the X-ray structure is much smaller. However, the
whole backbone of GP2 have had been kept fixed. The GP2/MHC complex has been then
further examined by using GOLD program.
5.2.2 FLU-MHC Docking Study
The partially minimized structure of FLU and MHC has been docked by using
AutoDock. Only the amide bonds of the FLU has benn kept fixed and the receptor has
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been taken as rigid. An implicit solvation effect has been used. The number of grid points
and the grid spacing used for the docking box are 96 x 72 x 72 and 0.375 Å, respectively.
The experimental and docked structures of FLU are shown in Figure 5.2. The resulting
RMSD is 0.42 Å, which is good agreement between the docked and experimental
structures.

Figure 5.2:
Overlay of experimental and docked FLU. Although only amide bonds of
FLU are fixed, the experimental structure has been reproduced with 0.42 Å values.
It is experimentally proven that while GP2 binds MHC poorly, FLU has a very
high relative binding affinity for MHC [5]. One interpretation is that GP2 binding is less
than FLU due to GP2’s increased flexibility. The results of docking studies on different
MHC complexes and also experimentally modified GP2-analogs are shown in the Tables
5.1 and 5.2. Results have been presented in terms of ∆G (kcal/mol) and number of Hbonds between the ligand and the receptor. Relative binding estimates have been obtained
by personal contact with Professor Wilson Meng from Pharmacy Department, Duquesne
University. RMSD between the X-ray crystallographic and the docked structures (in Å)
are given in Table 5.1. Two sets of numbers are reported for hydrogen bonds. The
numbers on the left have been obtained according to the MOE criterion; bond distance of
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HΛB is equal to or less then 3.5 Å, for H-bonding. The numbers on the right have been
obtained by using the following criteria; HΛB distance is equal to or less then 3.2 Å and
A - HΛB angle is between 135 – 180º [84].
Table 5.1:

Docking results for different peptide-MHC complexes
∆G (calc. Bind. Est.

PDB code

RMSD # of H-

Sequences of Ligands
(Å)

kcal/mol)

bonds

1QR1 (GP2) I I S A V V G I L

1

*

1.72

5

| 1

1HHI (FLU) G I L G F V F T L

5.8

*****

0.40

10 | 3

1HHJ

ILKEPVHGV

5.8

***

0.59

14 | 9

1HHG

TLTSCNTSV

4.8

***

1.10

14 | 11

1JF1

ELAGIGILTV

7.5

******

0.66

20 | 15

2CLR

MLLSVPLLLG

5.3

******

0.65

9

1HHK

LLFGYPVYV

5.5

*****

0.98

10 | 7

1HHH

F L P S D FF P S V

7.9

*****

0.79

10 | 6

1I4F

GVYDGREHTV

7.8

******

1.38

28 | 21

1JHT

ALGIGILTV

6.5

-

0.65

20 | 13

1DUY

LFGYPVYV

4.5

-

0.59

13 | 8

1DUZ

LLFGYPVYV

5.5

-

0.61

10 | 5

1B0G

ALWGFFPVL

4.3

-

1.88

8

| 3

1QSE

LLFGYPRYV

4.0

-

1.89

5

| 3

| 7

As can be seen from Table 5.1, the number of hydrogen bonds and the free energy
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values correlate with the experimental binding strengths only qualitatively. For the
complexes 2CLR, 1HHK, and 1HHH that are known as strong binders, the estimated
number of H-bonds are 7, 7, and 6 respectively. Thus, hydrogen bonding is not the only
factor affecting the ligand binding. Also, this might be due to the limitations of the
method which are discussed later.
Finally, docking studies have been performed for experimentally modified GP2
analogs and the proposed GP2 analogs. The results are shown in Tables 1 and 2,
respectively.
Table 5.2:
Docking results for experimentally modified GP2-analogs. This is a
qualitative correlation between the experimental binding affinities and the calculated
binding free energies. Also, number of H-bonds correlates qualitatively with the
experimental binding affinity data.
∆G (calc., relative)

Binding (exp*., rel.)

# of H-bonds

IISAVVGIL

1.0

1.0

5 | 1

ILSAVVGIV

4.7

2.4

8

|

5

FLSAVVGIL

5.0

2.2

11 |

8

FISAVVGIV

5.0

3.0

9

7

|

The correlation can be seen more clearly from the following plot, in Figure 5.3.
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Figure 5.3:
affinity plot.

Relative ∆G and number of H-bond vs. experimental relative binding

The R2 values for the correlations of calculated free energies and the number of
hydrogen bonds with experimental binding strengths are 0.846 and 0.686, respectively.
This shows that there is a poor correlation between the calculated and experimental
findings.
Finally, in Table 5.3, the docking results are shown for proposed GP2-like
ligands. According to docking results shown in Table 5.3, binding has been improved by
selective mutations. Based upon proposed modifications, IISAVVPIL has been studied
experimentally and found that it increased the binding affinity 68%. IISAVVPIL has
been studied because PRO has been thought to decrease the backbone flexibility, and also
experimentally stated that hydrophobic residues are preferred at position 3 [28]. The
interaction between the PRO7 and the receptor potential energy surface is shown in
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Figure 5.4.
Table 5.3:

Docking results for proposed modified GP2-analogs
∆G (calc., kcal/mol)

∆G (calc., relative)

IISAVVGIL

-4

1.0

8

IISAVVPIL

-18

4.5

12 | 9

IISAVPGIL

-21

5.3

11 | 7

IISANVGIL

-16

4.0

11

| 5

IISAQVGIL

-21

5.3

7

| 4

IISAFVGIL

-21

5.3

9

| 7

IMSAVVGIL

-21

5.3

11 | 8

IISPVVPIL

-23

5.8

10

# of H-bonds
| 1

| 6
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Figure 5.4: PRO 7 and receptor contacts. The hydrophobic and hydrophilic receptor
residues are shown in green and red color, respectively. The proline at position seven is
shown as ball-and-stick in element colors.
As can be seen from Figure 5.3, there is a hydrophobic interaction between PRO7
and the hydrophobic residues of the receptor. Another reason of the increased binding
affinity can be the decreased flexibility of the backbone due to the PRO at position 7.
The limitations of docking studies performed in this study were two-fold: First,
the receptor including crystallographic water molecules is fixed; also there are constraints
on the ligands. For GP2 the backbone has been kept fixed. Second, implicit solvent is
used. Third, only non-bonded terms have been taken into account for energy calculations.
Therefore, it gives qualitative results for energy values. However, the main advantage of
docking calculations in AutoDock is the reduced computational time. Therefore, these
studies can be useful to determine the best set of ligands for molecular dynamics studies
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that takes much longer time than docking calculations.

5.3

Docking results from GOLD
Since the backbone of GP2 had to be fixed in AutoDock calculations, the 1QR1

complex (GP2/MHC) was further investigated by using GOLD program, which allows
full flexibility for the ligand. The X-ray structure was reproduced without any constraints
on the ligand GP2, and the receptor was treated as rigid except the OH groups of SER,
THR, and TYR as well as the NH4 group LYS amino acids in the binding cleft. Nine
docked structures were identified as good in terms of RMSD values and the conformation
having the RMSD values (in Å): 1.31, 1.49, 1.53, 1.57, 1.68, 1.79,1.87, 1.98, and 2.03.
These structures were obtained by efficiently sampling the conformational space and also
by using different starting structures for the receptor. Also, the following parameters
affecting docking studies have been investigated systematically: Different radius values
for the docking sphere, different coordinates for the center of the binding cleft, different
molecular mechanics force fields, genetic algorithm settings, and different degrees of
flexibility for the ligand. The 20, 25 and 30 Å radius values were used and the 20 Å was
found optimum, because the better and faster results have been obtained with it. Also,
this size has been found big enough to provide enough space for the free conformational
change of the ligand. Amber 94 [83], Triposs [85] and CHARMM [86] force fields were
used and the latter was found to give better RMSD values. The receptor atoms 1521 and
1524 and also the coordinates (4.00, 16.1, -6.70) in x, y, z directions have been used. The
latter was found optimum based on RMSD values from the experimental structure. In
terms of genetic algorithm parameters; 10, 20, and 50 runs with default, doubled and
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tripled population size and number of operations have been used, and 50 runs with
doubled parameters have been found to give best and fastest results in terms of the
RMSD values from the X-ray crystallographic structure. Thus, the nine good structures,
having RMSD values smaller then 2.5 Å, have been obtained by using the optimum
values but with different receptor starting structures. The comparison of the best dockedstructure in terms of RMSD values out of these nine good structures and the X-ray
structure is shown in Figure 5.5.

Figure 5.5: Overlay of best docked GP2 in GOLD and the X-ray structure of GP2
(RMSD: 1.31 Å). The docked structure and experimental structure are shown in blue and
element colors, respectively as ball-and-stick.
The docked GP2 and the experimental data are in excellent agreement. Although
GP2 is a fairly long and flexible ligand, the experimental data was reproduced efficiently.
The criteria for being best docked-structure includes the binding energy values, H-bonds
and hydrophobic contacts between the ligand and the receptor as well as the RMSD
values. To obtain a better comparison, the interaction energy values were calculated by
using the MOE program. Also, each H-bond between the ligand and the receptor is
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examined carefully. The structures with lower RMSD values are expected to have lower
interaction energies and/or stronger H-bonds relative to each other. Neither the
interaction energy values nor the H-bond information correlates with the RMSD values.
Table 5.4 shows the RMSD values of nine docked structures as well as the number of Hbonds using MOE criterion.
Table 5.4:
The interaction energy values and number of H-bonds for the nine docked
structures in from GOLD.
GP2 / RMSD in Å

Eint (kcal)

# of H-bonds

X-ray

-103

8

1 / 1.31

-113

9

2 / 1.49

-90

10

3 / 1.53

-107

12

4 / 1.57

-81

6

5 / 1.68

-81

12

6 / 1.79

-32

7

7 / 1.87

-103

13

8 / 1.95

-105

12

9 / 2.03

-30

5

Some of the reasons for this lack of correlation might come from the following
reasons. First, the method used in calculating the energies may not be sufficient. More
thorough methods can be used for this purpose. For example, ZAP program [95] can be
used to calculate the binding free energy after scaling the energy expression for the
specific system used in this research, i.e., the peptide/MHC complexes. Second, the
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docking method may not be accurate enough. Since the fitness calculation used in GOLD
program is H-bonding oriented, it may not be able to locate the experimental data
accurately for hydrophobic ligands. Also, solvation effect is not added in docking
calculations in GOLD, and the receptor has a high degree of rigidity.
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Chapter 6

Conclusions

The binding free energy values from docking studies correlate weakly with the
experimental values and with the number of H-bonds between the ligand and MHC
receptor.

We find that hydrogen bonding is not the only factor affecting the binding.

Other forces like hydrophobic interactions and charged-charged interactions are in
operation.
Binding of GP2 to HLA-A2.1 has been improved by selective mutations. The center
residues have been mutated so that the main problem of flexibility that GP2 has in the
center can be addressed. The center residues of GP2 are bulged out of the binding cleft
and do not make stabilizing contacts with the residues of the receptor in the binding
groove. Based on these predictions the ligand IISAVVPIL has been studied
experimentally and found that it increased the binding 68%.
Although the X-ray structure of GP2 was reproduced by flexible docking calculations
in GOLD, the results need further work to calculate the binding free energies. For
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example, parameters in the binding energy expression of ZAP program can be scaled to
fit the known experimental values of peptide/MHC complexes, and then the binding
energies of docked GP2 models can be calculated utilizing ZAP.
In conclusion, the experimental data was reproduced qualitatively by using fast
docking calculations, and these findings can be useful for more thorough computational
methods like molecular mechanics.
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